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Abstract 
C-Kit (CD117), the receptor for the stem cell
factor, a growth factor for melanocyte migra-
tion and proliferation, has shown differential
immunostaining in various benign and malig-
nant melanocytic lesions. The purpose of this
study is to compare c-Kit immunostaining in
benign nevi and in primary and metastatic
malignant melanomas, to determine whether
c-Kit can aid in the differential diagnosis of
these lesions. c-Kit immunostaining was per-
formed in 60 cases of pigmented lesions,
including 39 benign nevi (5 blue nevi, 5 intra-
dermal nevi, 3 junctional nevi, 15 cases of pri-
mary compound nevus, 11 cases of Spitz
nevus), 18 cases of primary malignant
melanoma and 3 cases of metastatic
melanoma. The vast majority of nevi and
melanomas examined in this study were posi-
tive for c-Kit, with minimal differences
between benign and malignant lesions. C-Kit
cytoplasmatic immunoreactivity in the
intraepidermal proliferating nevus cells, was
detected in benign pigmented lesions as well
as in malignant melanoma, increasing with
the age of patients (P=0.007) in both groups.
The patient’s age at presentation appeared to
be the variable able to cluster benign and
malignant pigmented lesions. The percentage
of c-Kit positive intraepidermal nevus cells was
better associated with age despite other vari-
ables (P=0.014). The intensity and percentage
of c-Kit positivity in the proliferating nevus
cells in the dermis was significantly increased
in malignant melanocytic lesions (P=0.015
and P=0.008) compared to benign lesions
(compound  melanocytic nevi, Spitz nevi,
intradermal nevi, blue nevi). Immunostaning
for c-Kit in metastatic melanomas was nega-
tive. Interestingly in two cases of melanoma
occurring on a pre-existent nevus, the
melanoma tumor cells showed strong cytoplas-
matic and membranous positivity for c-kit, in
contrast with the absence of any immunoreac-
tivity in pre-existent intradermal nevus cells.
C-Kit does not appear to be a strong immuno-
histochemical marker for distinguishing
melanoma from melanocytic nevi, if we consid-
er c-Kit expression in intraepidermal prolifer-
ating cells. The c-Kit expression in proliferat-
ing melanocytes in the dermis could help in
the differential diagnosis between a superfi-
cial spreading melanoma (with dermis inva-
sion) and a compound nevus or an intradermal
nevus. Finally, c-Kit could be a good diagnostic
tool for distinguishing benign compound nevi
from malignant melanocytic lesions with der-
mis invasion and to differentiate metastatic
melanoma from primary melanoma.
Introduction
C-Kit is a transmembrane receptor tyrosine
kinase that binds stem cell factor (SCF).1-3 C-
Kit is encoded by the kit proto-oncogene, local-
ized to human chromosome 4 and to mouse
chromosome 5.4,5 The c-Kit/SCF interaction is
critical for the survival and development of
stem cells involved in hematopoiesis,6 in pan-
creas development7 and in melanogenesis.8
The c-Kit gene product is expressed in several
normal cell types including mast cells, the
interstizial cells of Cajal and the melanocytes
and epithelial cells of the breast.9 Alterations
in c-Kit expression are seen in a variety of neo-
plasms including mastocitosis, gastrointesti-
nal cell tumors (GISTs) and germ cell tumors.10
After binding to the stem cell factor, c-Kit
begins a signal cascade that contributes to the
growth and differentiation of multiple
hematopoietic lineages.11 Previous studies
have shown that c-Kit is expressed in junction-
al components of benign compound nevi12 and
it is frequently positive in superficial spread-
ing melanoma (early stage);13 this positivity is
lost in the vertical growth phase of invasive
melanoma.14-17 More interestingly, a loss of c-
Kit immunostaining from primary malignant
melanoma to metastatic melanoma in the
same patients has been reported.18 Malignant
transformation of melanocytes is associated
with changes in the expression of c-Kit.
Several studies have demonstrated that the
progression of human melanoma is associated
with the loss of expression of c-Kit.8,14,15 These
studies revealed that expression of the tyro-
sine kinase receptor encoded by the c-Kit
proto-oncogene gradually declines during
growth and invasion of human melanoma.8,14-16
The explanation for the loss of c-Kit expression
in melanoma progression has still not been
fully explained. Since SCF plays a crucial role
in melanocyte proliferation, there is an inter-
est in the diagnostic or treatment potentials of
c-Kit in melanocytic lesions, especially in
melanoma. Given the heterogeneous appear-
ance of malignant melanoma, diagnostic diffi-
culties19 and poor inter-observer reproducibili-
ty, this study was designed to assess whether
the expression of c-Kit identifies differences
in melanocytic lesions, considering benign
nevi, primary melanoma and metastatic
melanoma.
Materials and Methods
A retrospective study was initiated to review
the medical records of all patients with a diag-
nosis of benign nevus and malignant
melanoma between 2008 and 2009 at the
Anatomy Pathology Division, University of
Cagliari, Italy. Through a careful clinical-
pathological correlation, we identified 60 cases
of pigmented lesions grouped into 39 cases of
benign nevus (5 blue nevi, 5 intradermal nevi,
3 junctional nevi, 15 cases of primary com-
pound nevus, 11 cases of Spitz nevus), 18
cases of primary melanoma and 3 cases of
metastatic melanoma. Five micron paraffin
sections from benign and malignant
melanocytic lesions were immunostained for
CD117, c-Kit, (cod,A4502 polyclonal rabbit
anti-Human CD117, c-Kit, DAKO, Carpinteria,
CA, USA), diluted 1:200. The incubation time
of the primary antibody was 30 min. Heat
induced antigen retrieval was adopted (20 min
at 98° in Tris/edta pH9). We used the Dako
cytomation LSAB2 system-HRP (DAKO) that is
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based on a modified labelled avidin-biotin
(LAB) technique in which a biotinylated sec-
ondary antibody forms a complex with peroxi-
dase-coniugated strepavidin molecules.
Endogenous peroxidase activity was quenched
by incubating (5 min) specimens with 3%
hydrogen peroxide. The staining was complet-
ed after incubation (10 min) with 3-amino-
9.ethyl carbazole (AEC) substrate chromogen,
which resulted in a red-colored precipitate at
the antigen site. Slides were reviewed by two
pathologists who were not aware of the clinical
data, and evaluated it for both tumor cell per-
centage and intensity of immunoreactivity.
The percentage of positive cells was recorded
as 0=negative; 1=<5% of cells staining; 2=5-
50% of cells staining; 3=51-95% of cells stain-
ing; and 4=>95% of cells staining.20 Intensity
was scored as 0 (negative), 1+ (weak), 2+
(moderate), and 3+ (strong), and evaluated by
comparing contiguous epidermal melanocytes
and interstitial mast cells (considering moder-
ately positive contiguous melanocytes (2+)
and intensely positive (3+) dermal mast cells).
The product of the percentage and the intensi-
ty score was used as the final measure of the
staining. Differences in c-Kit immunoreactivi-
ty in the top and in the bottom of lesions were
as well evaluated. Further variables considered
in the present study were: maximal dimen-
sions of lesions, age and sex of patients. Statistical analysis
The variables involved in the analysis are
semiquantitative, more precisely they are
ordered polytomous categorical values. This
means that, if we consider, for example, two
values for the percentage of positive cells, say
1 and 2, these values represent two sets of per-
centages, less than 10% and between 10 and
50%. Therefore, the difference between values
1 and 2 cannot be evaluated simply on a linear
scale by saying, for instance, that it is 1. In
order to estimate the relationship between
scores (percentage of positive cells and inten-
sity) and all other variables, it is more appro-
priate to use the proportional odds model.21
The P-values are obtained with the use of the
proportional odds model. Essentially this is a
generalization of the regression model suit-
able for polytomous data. For a given score
variable, different regression models can be
estimated according to the chosen explanatory
variables. We come up with the best model
according to the Deviance Criteria.21 The P-val-
ues, in the Results section, illustrate the sig-
nificance levels of the regression coefficients
that relate the score to the specified variable.
The pre-selected significance is 5%. Only for
the sake of comparison did we report t-tests
using Welch correction, to assess the signifi-
cance of the relation between a score variable
and the group of pigmented lesions. Such
analyses were appropriate if the collected
score variables (and even their product) were
interpretable under a linear scale. The data are
presented as mean ± SEM.
Results 
Clinical-pathological features ofmelanocytic lesions
Clinical features of melanocytic lesions,
recruited in our study, are presented in Table
1. The 5 blue nevi were from 5 subjects (4
males and 1 female) ranging from 14 to 77
years-old (mean age 45.8). Histologically, they
were characterized by the presence of elongat-
ed melanocytes with thin, pigmented cytoplas-
matic dendrites scattered between undis-
turbed collagen fibers and a variable number of
melanophages. The 18 melanomas included 1
in situ melanoma from a 75 years-old female, 3
in situ melanoma from 3 females ranging from
46 to 76 years-old (mean age 59), 14 superfi-
cial spreading melanomas from 14 subjects (6
males and 8 females) ranging from 25 to 78
years-old (mean age 42.8) (Table 2).
Histologically, they were characterized by
asymmetric proliferations of atypical
melanocytes associated with occasional page-
toid spread, mitotic activity and inflammatory
reaction. Primary cutaneous melanomas were
invasive with Clark’s levels ranging from II to
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Table 1. Clinical data.
No. Sex Age Mean Anatomical site
(M:F) range age
(years) (years)
BluNevi 5 4:1 14-77 45.8 Foot, arm, scalp(3)
Acral melanoma 1 0:1 - - Foot
Melanoma in situ 3 3:0 46-76 59 Back, thorax, foot
Supeficial spreading 14 6:8 25-78 42.8 arm, back (6), thigh, 
melanoma leg(3), breast, thorax, abdomen
Metastasis 3 3:0 59-77 69.6 Wrist, abdomen, lynphonode
Dermal nevi 5 2:3 19-30 26.4 Vulva, back, abdomen, scalp, neck
Junctional nevi 3 0:3 33-34 33.3 Back, leg, foot
Compound nevi 15 7:8 21-60 32.6 back(8), thorax, abdomen(2), leg, 
pube, shoulder, temple,
Spitz nevi 11 3:8 3-50 20,2 arm(3), leg(2), hand(2), shoulder,
high, back(2)
Table 2. Characteristics of eighteen primary cutaneous melanomas.
Type Clark Breslow Radial phase Vertical phase Site
1 acral II 1.2 + Foot
2 SSM IV 1.1 + Back
3 SSM II 0.5 + Abdomen
4 SSM IV 1.6 + Arm
5 in situ I / / / Back
6 SSM II 0.6 + Leg
7 SSM IV 0.8 + Back
8 SSM II 0.2 + Back
9 SSM IV 1.0 + Thigh
10 in situ I / / / Thorax
11 SSM IV 1.0 + Leg
12 SSM II 0.5 + Breast
13 in situ I / / / Foot
14 SSM II 0.2 + Leg
15 SSM IV 0.7 + Back
16 SSM II 0.2 + Back
17 SSM II 0.3 + Back
18 SSM IV 2.8 + Thorax
SSM, superficial spreading melanoma.
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IV, and Breslow depths ranging from 0.5 up to
2.8 mm (Table 2). The 3 metastasis were from
3 male subjects, ranging from 59 to 77 years-
old (mean age 69.6). The 23 benign nevi
include 3 junctional types from 3 females rang-
ing from 33 to 34 years-old; 5 dermal types
from 5 subjects (2 males and 3 females) rang-
ing from 19 to 30 years-old (mean age 26.4), 15
compound types from 15 subjects (7 males and
8 females) ranging from 21 to 60 years-old
(mean age 32.6). Histologically, junctional
nevi were characterized by small melanocytes
without cytological atypia, organized both in
regular aggregates at basis of rete ridges or in
lentiginous fashion at dermo-epidermal junc-
tion; intradermal nevi were characterized by
banal melanocytes organized in aggregates
with regular maturation. The 11 Spitz nevi
included: 5 junctional types and 6 compound
types from 11 subjects (3 males and 8 females)
ranging from 3 to 50 years old (mean age
20.2). Histologically they were characterized
by spindle and epithelioid melanocytes
arranged in fascicles or nests with clefting and
occasional central spread of melanocytes.
Patients with benign melanocytic lesions were
younger (29.6±2.6) than patients with
melanoma (47.8±3.8) and patients with
metastatic melanoma (69.7±5.4). The mean
Breslow thickness for melanomas was
0.85±0.18 and it has never entered into the
statistical analysis (Table 2).C-Kit expression by immunohisto-chemistry
Available data of the c-Kit immunohisto-
chemical staining are presented in Tables 3
and 4. Table 3 summarizes the values of c-Kit
intensity staining and Table 4 summarizes the
values of percentage of c-Kit positive nevus
cells. All 5 blue nevi showed slight cytoplasmat-
ic-membranous positivity of fusate nevus cells
with percentage of c-Kit stained cell <5%,
without difference of c-Kit immunohistochem-
ical expression between the top and bottom of
lesions. As for the 18 cases of melanoma, the 3
cases of melanoma in situ, one case showed
slight (1+) cytoplasmatic positivity with c-Kit
stained cell percentage <5%, the second case
showed moderate membranous positivity (2+)
with c-Kit stained cell percentage 51-95 % and
the third case (acral type) showed strong (3+)
positivity with both membranous and cytoplas-
matic pattern, with percentage of c-Kit stained
cell >95%. 
The acral melanoma showed strong cyto-
plasmatic positivity (3+), with percentage of c-
Kit stained cell >95% in the junctional compo-
nent; c-Kit expression in dermal component
was moderate (2+) cytoplasmatic, with c-Kit
stained cell percentage 51-95%, without sub-
stantial difference between the top and the
bottom of lesions. The 14 cases of superficial
spreading melanoma, showed slight cytoplas-
matic positivity in the junctional component
(1+) in two cases; moderate intensity (2+) in
7 cases (5 cytoplasmatic, 2 both cytoplasmatic
and membranous); strong positivity (3+) in 6
cases (4 expressed both cytoplasmatic and
membranous pattern and 2 only cytoplasmat-
ic), with percentage of c-Kit stained cell > 5%
in one case, between 5-50% in 5 cases,
between 51-95% in 3 cases and >95% in 5
cases. The intensity of c-Kit stained dermal
cell  was slight (1+) in 5 cases (5 cytoplasmat-
ic); moderate intensity (2+) in 4 cases (4 cyto-
plasmatic and 2 with cytoplasmatic and mem-
branous pattern); strong intensity (3+) in
only one case (both cytoplasmatic and mem-
branous pattern); with percentage of c-Kit
Original paper
Table 3. Immunohistochemical data. 
Intensity c-Kit staining in tumors cells
Epidermis Dermis
Negative Weak Moderate Strong Negative Weak Moderate Strong
n. 0 1 2 3 0 1 2 3
BluNevi 5 0 0 0 0 - 5 - _
Acral melanoma 1 0 0 0 0 0 1 0
Melanoma in situ 3 0 1 1 1 0 0 0 0
Supeficial spreading melanoma 14 0 2 7 5 4 5 4 1
Metastasis 3 - - - - 3 0 0 0
Dermal nevi 5 0 0 0 0 1 2 1 1
Junctional nevi 3 0 0 0 3 - - - -
Compound nevi 15 0 2 10 3 4 8 2 1
Spitz nevi 11 0 10 1 0 3 3 0 0
Table 4. immunohistochemical data.
Percentage of tumors cells expressing c_Kit
Epidermis Dermis
Negative <5% 5-50% 51-95% >95% Negative <5% 5-50% 51-95% >95%
n. 0 1 2 3 0 1 2 3
BluNevi 5 - - - - - 0 5 0 0 0
Acral melanoma 1 0 0 0 0 1 0 0 0 1 0
Melanoma in situ 3 0 1 0 1 1 - - - - -
Supeficial spreading melanoma 14 0 1 5 3 5 3 3 4 4 0
Metastasis 3 - - - - - 3 0 0 0 0
Dermal nevi 5 - - - - - 1 2 1 1 0
Junctional nevi 3 0 0 1 1 1 - - - - -
Compound nevi 15 0 0 6 8 1 4 3 6 2 -
Spitz nevi 11 0 3 4 4 0 3 2 1 0 0
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stained dermal cell <5% in 3 cases, between 5-
50% in 3 cases and 51-95% in 4 cases. The top-
bottom evaluation showed seven cases with
diffuse positivity without differences in the
lesions; three cases showed evident
immunoreactivity on the top with gradual
decrease to the bottom of lesions. C-kit
immunoreactivity was negative in 3 cases of
metastatic melanoma. The 3 cases of junction-
al nevus showed strong c-Kit positivity (3+) (2
membranous, 1 cytoplasmatic) with c-Kit
stained cell percentage equal to 5-50% in one
case, 51-95 % in another case and >95% in the
last one. The 15 primary compound nevus,
showed slight epidermic membranous, positiv-
ity (1+) in 2 cases, moderate intensity (2+) in
10 cases (5 membranous and 5 cytoplasmatic)
and strong membranous positivity (3+) in
three cases. The percentage of c-Kit stained
cell (Table 4) in the epidermis were between 5-
50% in 6 cases, between 51-95% in 8 cases and
>95% in one case. The c-Kit immunoreactivity
in the dermic component (Table 3) was slight
(1+) in 8 cases (cytoplasmatic), moderate pos-
itivity (2+) in two cases (membranous),
strong (3+) in one cases (cytoplasmatic),
absent in four cases. The percentage c-Kit
stained cell in the dermic component (Table 4)
was <5% in three cases and between 5-50% in
six cases; 51- 95% in two cases, absent in four
cases. The top-bottom evaluation showed in 11
cases evident c-Kit positivity in the top with
gradual reduction to bottom of lesions whereas
in the remaining four cases c-Kit immunoreac-
tivity was homogeneous and diffused to all
areas of lesions. In the 5 intradermal nevi, c-
Kit immunoreactivity in the dermic component
(Table 3) was slight (1+) in two cases (cito-
plasmatic and membranous in one case, only
citoplasmatic in the other one), moderate (2+)
in one case (citoplasmatic and membranous),
strong (3+) in one case (membranous),
absent in one case. The percentage of c-Kit
stained cell was <5% in two cases and between
5-50% in one case; 51-95% in one case, absent
in the last case. The top-bottom evaluation was
not performed for the absence of the epidermic
component. As for the 11 cases of Spitz nevus
(5 junctional and 6 compound), the junctional
Spitz nevi showed slight positivity (1+) in 4
cases and moderate positivity (2+) in one
case; the c-Kit stained cell percentage was
between 5-50% in 3 cases, and 51-95% in the
two remaining cases. All 6 compound Spitz
nevi showed slight epidermic positivity (2
membranous and 4 cytoplasmatic), the per-
centage of c-Kit stained cell was <5% in 3
cases, 5-50% in one case, 51-95% in two cases.
The dermic immunoreactivity for c-Kit was
slight (1+) in three cases (cytoplasmatic) with
c-Kit stained cell percentage <5% in two cases
and between 5-50% in one case, absent in the
remaining three cases. The top-bottom evalua-
tion in the six compound Spits nevi showed
evident c-Kit positivity on top with a gradual
decrease to bottom of the lesions in all cases.
The vast majority of nevi and melanomas
examined in this study were positive for c-Kit,
with minimal differences, at microscopic
observation, between benign and malignant
lesions and with a decrease of c-Kit expression
from top to bottom of the lesions. C-Kit was
equally expressed in the junctional component
of any melanocytic lesions both benign and
malignant (Figures 1 and 2). Differences were
found in c-Kit immunoreactivity between the
intradermal component of benign and malig-
nant melanocytic lesions. In particular, in
superficial spreading melanoma with initial
dermal invasion, radial growth phase,
immunostaning for c-Kit showed higher
grades of intensity and a higher percentage of
positive melanocytic cells (Figure 3; Table 3
and 4). On the contrary in compound nevi,
immunostaning was stronger in the junctional
component, with a progressive decrease from
the top to bottom of the lesion (Figure 4). C-kit
staining of the intraepidermal nevus cells
demonstrated a cytoplasmic pattern admixed
with a membranous pattern. According to the
proportional odds model, there was a signifi-
cant association between the intensity of c-Kit
staining in intraepidermal nevus cells and the
increasing age of the patient (P=0.007) (Table
5). Also the percentage of c-Kit-positive
intraepidermal nevus cells resulted positively
considering the patient’s age increasing
(P=0.014) (Table 5); in one case, we observed
that the intensity and percentage of positive
intraepidermal nevus cell was related to the
diameter of the lesion. Intensity of c-Kit
expression in dermal melanocytes was signifi-
cantly higher in the melanoma group com-
pared to the benign lesion group (P=0.015), as
well as the percentage of c-Kit-positive dermal
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Figure 1. Representative staining results in a case of compound nevus. A) H&E staining
showing a proliferation of junctional and dermal melanocytes with symmetrical pattern
and no evidence of cytological dysplasia; B) C-Kit immunohistochemistry showing strong
(membranous and cytoplasmatic) expression in the junctional component of compound
nevus and weak expression in the dermal component with gradual decrease to the bottom
of the lesion. In the reticular dermis frequent c-Kit positive mastcell. Scale bars: 100 µm.
Figure 2. Representative staining results in an interesting case of superficial spreading
melanoma on a compound nevus. A) H-E stain showing an in situ superficial spreading
melanoma (left) and a compound nevus with a symmetrical pattern and no evidence of
cytological dysplasia; B) Prominent CD 117 immunohistochemical staining only at der-
moepidermal junction and focal positivity of bottom in the dermal component of com-
pound nevus; C) CD 117 immunohistochemical staining only at dermoepidermal junc-
tion of in situ superficial spreading melanoma; D) CD 117 immunohistochemical stain-
ing focal positivity at the bottom of the dermal component of compound nevus. A,B, scale
bars 200 µm; C,D, scale bars: 20 µm.
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melanoma cells (P=0.008) (Table 5).
Interestingly, dermal staining of metastatic
melanoma was negative (Figure 5). These
final models (represented in Table 5) were
obtained after considering age, type, sex and
dimension of lesions in order to account for
possible confounders. For the sake of compari-
son, in Table 6 we report the analysis using
product staining and t-test with Welch correc-
tion as performed by Zhu et al.22 For instance,
association between expression in dermal
melanocytes in the melanoma group compared
to benign lesion has a P-value of 0.032, which
is higher than 0.015 (Table 5 and 6). Finally,
we also reported no association between epi-
dermal melanocytes in the melanoma group
compared to benign lesions with a P-value
much higher than 0.057 (either in intensity or
percentage).
Discussion
Benign melanocytic nevi may have occa-
sional cosmetic significance but, for the most
part, they are important only in relation to
melanoma. Nevi are the most important simu-
lants of melanoma, both clinically and histolog-
ically, and can usually be reliably distinguished
from melanoma using published criteria.
Some benign lesions are characterized by a
greater degree of atypia and may be more dif-
ficult to diagnose.19 Malignant melanoma
remains the most contentious of all diagnoses
in dermatophatology. While classic histologic
criteria have been extensively described over
the past four/five decades, interpretation of
these criteria remains difficult.23,24 Currently,
separation of melanomas from nevi is based
primarily on light microscopic interpretation
of hematoxylin and eosin-stained sections,
with limited assistance from immunohistology.
The heterogeneous histological features of
melanoma may often overlap with melanocytic
nevi. For this reason, pathologists have looked
to immunohistochemistry to assist with diffi-
cult cases. In this challenging diagnostic sce-
nario, many studies have been performed to
identify molecular markers that might distin-
guish benign lesions from malignant
melanocytic ones and also the various progres-
sion stages in primary malignant melanoma of
the skin.25,26 C-Kit immunoreactivity has been
proposed as a useful tool in the differential
diagnosis between deep soft tissue or visceral
lesions with melanocytic differentiation; posi-
tive staining for c-Kit could exclude the diag-
nosis of clear cell sarcoma, but it is compatible
with the diagnosis of metastatic melanoma.27
Kashani-Sabet et al. run some transcriptome
analyses that show the differential expression
of several genes in melanoma progression.28
Original paper
Table 5. Results with the proportional odds model (Coefficient ± Standard Error, P-
value). The first column indicates the specific model in terms of Dependent
Variable/Explanatory Variable. Such models have been chosen according to the Deviance
Criteria. 
Model Coefficient ± Standard Error, P-value of explanatory variables
Age* Pigmented lesions**
Epi.Int | Age -0.05±0.02, P=0.007
Epi.Perc | Age -0.04±0.02, P=0.014
Der.Int | Pigmented lesions -1.82±0.73, P=0.015
Der.Perc | Pigmented lesions -1.89±0.70, P=0.008
*Negative coefficients indicate increase with respect to age;**negative coefficients indicate increase in malignant vs. benign
lesions.Epi.Int, epidermal melanocytes intensity of c-Kit stain; Epi.Per., epidermal melanocytes percentage of c-Kit stain; Der.Int.,
dermal melanocytes intensity of c-Kit stain; Der.Perc., dermal melanocytes percentage of c-Kit stain.
Table 6. Results of CD117 immunohistochemical product staining (mean ± SEM, P-
value); the P-value refers to the significance of the difference between benign and malig-
nant pigmented lesions for column benign; malignant and metastatic for column malig-
nant; metastatic and benign for column metastatic. Such significance values are calculat-
ed with the usual t-test.
Benign Primary malignant Metastatic
nevus melanoma melanoma
Number of cases 39 18 3
Epidermal melanocytes 4.7±0.5, P=0.057 7.0±1.0, n.a. n.a., n.a.
Dermal melanocytes 1.8±0.4, P=0.032 4.0±0.8, P<0.001 0±0, P<0.001
n.a., not available.
Figure 3. Representative staining in a case of superficial spreading melanoma (vertical
growth phase). A) H&E staining showing a melanocytic proliferation with architectural
disorder; B) prominent c-Kit immunostaining both at the junctional and dermic compo-
nent. Scale bars: 200 µm.
Figure 4. Representative staining in a case of Spitz nevus. A) H&E staining showing a pro-
liferation of spindle and epitelioid melanocytes with symmetrical pattern and no evidence
of cytological dysplasia; B) prominent c-Kit immunohistochemical staining at dermoepi-
dermal junction and progressive decrease positivity in the dermis. Scale bars: 200 µm.
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They also performed a multi-marker diagnostic
assay using 5 markers (ARPC2, FN1, RGS1,
SPP1 and WNT2), which are over-expressed in
melanoma cells. Gould Rothberg et al. pro-
posed that the ratio of nuclear to non-nuclear
HMB45 immunofluorescence staining may be
useful in the diagnosis of melanocytic
lesions.29 Recent data has shown also that
PAX3 is commonly expressed in primary
melanoma samples (21/58), but significantly
less frequently in benign pigmented lesions
(9/75).30 Additionally, IMP-3 (insulin-like
growth factor-II messenger RNA-binding pro-
tein-3) may have diagnostic utility in distin-
guish melanoma from benign nevi, displastic
nevi and Spitz nevi.31 Zhu et al. proposed that
CD117 is unlikely to be a useful diagnostic tool
to differentiate Spitz nevus from malignant
melanoma but may be useful to differentiate
metastatic melanoma from primary melanoma
in patients who have a history of melanoma
and who presented with new dermal lesions.22
Increased Wilms’ tumor 1 protein (WT1)
expression has been proposed as a marker of
melanoma cells. However, as a single
immunostaining marker, WT1 is not sufficient
to distinguish melanoma from benign
melanocytic nevi.32 Hillard et al. retained that
the staining pattern for p16 in desmoplastic
melanomas and Spitz nevi, in conjunction with
the histopathologic features, S100 staining,
Ki67 proliferation index and clinical scenario
may aid in the difficult differential diagnosis
between these two entities.33 Ribè and Scot
McNutt assessed an immunohistochemical
test for S100A6 protein to differentiate Spitz
nevi from melanoma and melanocytic nevi:34
this marker can be used when the distinction
is very difficult or controversial in routine
studies, especially when there is a junctional
component. CD117 is an indicator of malig-
nant proliferative process and reported that
while 59% of benign melanocytic nevi express
c-Kit, 100% of displastic nevi and 96% of pri-
mary melanoma express c-Kit.8 In our study,
we observed that c-Kit, in the junctional com-
ponent of benign and malignant lesions, is
constantly expressed, with minimal differ-
ences between intensity and percentage, while
in the dermal component of both benign nevi
and melanomas there is a decrease in expres-
sion of c-Kit. In metastatic melanoma with
only dermal component, c-Kit expression was
absent or minimally present as well as been
reported by Zhu et al. and Guerriere et al.22,25
Besides a decrease of c-Kit expression in the
intradermal component of pigmented lesions,
our statistical data showed  higher values of
the intensity and of the percentage c-Kit posi-
tive cells in melanomas. Our study suggests
that c-Kit is not a specific marker discrimina-
tor between junctional component of benign
melanocytic nevi and superficial spreading
melanoma. In fact the intensity and percent-
age of c-Kit in intraepidermal melanocytes was
not correlated with the type of pigmented
lesions (benign melanocytic nevi and superfi-
cial spreading melanoma). In fact also in junc-
tional nevi, compound nevi, and Spitz nevi, the
intraepidermic melanocytes showed intense
and diffuse c-Kit positivity as well as the prolif-
erant melanocytes of melanoma in situ and of
superficial spreading melanoma. At microscop-
ic analysis we observed, in the intradermic
component of pigmented lesions, that intensi-
ty and percentage of c-Kit positive cells was
higher in melanomas than in nevi, this is
moreover proved by statistical analysis. It was
speculated that in the model of tumor progres-
sion in malignant melanoma (atypical
intraepidermic proliferation followed by a radi-
al growth phase then a vertical growth phase)
to acquire proliferative advantage and escape
from epidermal boundaries, melanoma cells
should lose Kit expression.35 This hypothesis
was supported by previous observations in
which Kit expression in melanoma was strong
in the melanoma in situ and in the junctional
component of invasive lesions, but was lost
once the melanoma became invasive and
metastatic.15,25 Also our data supported this
intriguing hypothesis, in fact our superficial
spreading melanomas, in radial phase or in
vertical phase, even though with an intensity
and percentage of c-Kit positive dermic nevus
cells higher than in the benign intradermic
and compound nevi, showed an initial
decrease of c-Kit expression from the top to
the bottom of lesions. Only one case of super-
ficial spreading melanoma, in the vertical
growth phase, showed diffuse and intense c-
Kit positivity (Figure 3). Also the real loss of c-
kit expression in our three metastasis corrob-
orate this hypothesis. Marked intensity in
junctional components and gradual decrease
of c-Kit expression in dermal component is
observed both in intradermal and compound
nevi, up to range a real loss of c-Kit expression
in the bottom of lesions, as was observed in
melanomas. We supposed that, in benign nevi,
this junctional marked c-Kit intensity with
gradual decrease in dermal component, could
be explained as result of a motogen effect.35 C-
Kit expression could indicate melanocytes dur-
ing their migration phase. Therefore, the
migratory direction in melanocytic lesions is
from dermis to epidermis.35 We additionally
observed a real c-Kit over-expression in two
cases of acral melanoma, even if Kit mutation
is not tested. This observation is not in con-
trast to literature data. Curtin et al. found that
more than a third of the acral, mucosal and sun
induced melanomas without detectable Kit
mutation or copy number increase, showed
over-expression of Kit by immunohistochem-
istry led to hypothesize that other mechanisms
than gene mutation or amplification could
explain the observed Kit over-expression.36 In
our study, variables like intensity and percent-
age increased only if correlated with the
patient’s age. However, scores of intensity and
percentage of c-Kit, only in dermal
melanocytes resulted statistically different
between benign and malignant lesions: those
variables were more expressed in melanoma
cells than in nevus cells. In summary on the
basis of our data, c-Kit should not be consid-
ered as an indicator of malignant proliferative
process but may be considered as a result of
the motogenic effect of proliferating
melanocytes. It could further be a useful mark-
er to differentiate primary melanoma from
compound nevi while seeming to be not entire-
ly useful to differentiate melanocytic junction-
al nevi from melanoma in situ or superficial
spreading melanoma in radial phase. 
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